These observations align with other made by large international leukemia consortia, including the European Group for the Immunological characterization of leukemias (EGIL) and the Current National Comprehensive Cancer Network (NCCN), which offer immunophenotypic frameworks (e.g., BI–BIII, Pro-B to Mature B-ALL) based on immunophenotype data (46–48). The gene discussed is CACNA1A; the disease is acute lymphoblastic leukemia.